This clinical-stage biopharmaceutical company develops treatments and therapies that target and degrade disease-related proteins using proprietary technology, with drug developments in (immuno)oncology and neurology.
This clinical-stage biopharmaceutical company develops treatments and therapies that target and degrade disease-related proteins using proprietary technology, with drug developments in (immuno)oncology and neurology.